Mehmet Hanifi KOKAÇYA, Faruk KURHAN, Musa ŞAHPOLAT

Sibutramin içeren reçetesiz zayıflama ürününün indüklediği ilk manik hecme

Sibutramin obesite tedavisinde kullanılan serotonin, noradrenalin ve daha zayıf bir şekilde de dopamin geri alımını engelleyen ve birçok psikiyatrik yan etkileri olan bir beta feniletilamindir. Kardiyolojik yan etkileri nedeniyle yasaklanmış olmasına rağmen halen internet üzerinden “Zayıflama hapı” adı altında satışı devam etmektedir. Antidepresanların manik veya hipomanik kaymaya neden olabilecekleri bilinmektedir. Sibutramin, antidepresan özelliğinden dolayı manik veya hipomanik kaymaya neden olabilir. Biz, internetten satın aldığı sibutramin içeren bir zayıflama ilacını kullandıktan hemen sonra ilk kez manik bir hecme geçiren altı ay sonrasında ise servisimize yine manik hecme nedeniyle yatırılan bir adölesanı sunuyoruz.

Anahtar Kelimeler:

sibutramin, mani, zayıflama ilaçları

First manic episode induced by over the counter slimming drug that contains sibutramine

Sibutramine, a serotonin, noradrenalin and to a lesser extent dopamine reuptake inhibitor, is a beta phenyletylamine used in obesity treatment and has many psychiatric side effects. Although, prohibited due to cardiologic side effects, it is still being sold as “Slimming pills” via internet. It is known that antidepressants can cause manic or hypomanic shifts. Since sibutramine has an antidepressant activity it may cause manic or hypomanic shifts. We present an adolescent who had his first manic episode after using sliming pills, which contain sibutramine, and was admitted to our service for his second manic episode 6 months after his first episode.

Keywords:

sibutramine, mania, slimming pills,

PDF

___

Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008;9:378-87.
Waszkiewicz N, Zalewska-Szajda B, Szajda SD, Simonienko K, Zalewska A, Szulc A. Sibutramine-induced mania as the first manifestation of bipolar disorder. BMC Psychiatry. 2012;12:43.
Buckett WR, Thomas PC, Luscombe GP The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenerjic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575-84.
Nathan PJ, O’Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther. 2011;5:490-505.
T.C. Sağlık Bakanlığı Reductil (Sibutramin) hakkında, Sağlık Bakanlığı İlaç ve Eczacılık Genel Müdürlüğü 22.01.2010 tarih 006064 sayılı yazısı.
Binbay T. First-episode mania with psychotic features induced by over-the-counter diet aids containing sibutramine. Turk Psikiyatri Derg. 2010;4:335-7.
T.C. Sağlık Bakanlığı Pepper Time Kapsül (Biber hapı) hakkında, Sağlık Bakanlığı İlaç ve Eczacılık Genel Müdürlüğü (05.08.2010 tarih ve B.10.0.İEG.0.11.00.01-330.06 sayılı yazısı.
Müller D, Weinmann W, Hermanns-Clausen M, Chinese slimming capsules containing sibutramine sold overthe Internet: a caseseries. Dtsch Arztebl Int. 2009;106:218-22.
Jung J, Hermanns-Clausen M, Weinmann W. Anorectic sibutramine detected in a Chinese herbal drug for weightloss. Forensic Sci Int. 2006;161:221-2.
Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130-8.
Dunner DL, D’Souza DN, Kajdasz DK, Dekte MJ, Russell JM. Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression. Journal of Affective Disorders. 2005;87:115-9.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25:871-80.
Bulut M, Virit O, Selek S, Savas E, Bülbül F, Dalkilic A, et al. Manic Attack Possibly Triggered by Sulbutiamine: Case Report. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2011;31:487.
Fiorentini S, Russo D, D’Amato A, Limpido L, Bersani G. Sibutramine-related panicattack: a clinical case of apparent resolution with paroxetine. Riv Psichiatr. 2009;44:64-7.
Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safeuse. Obes Rev. 2008;9:378-87.
Dogangun B, Bolat N, Rustamov I, Kayaalp L. Sibutramineinduced psychotic episode in an adolescent. J Psychosom Res. 2008;65:505-6.
Fu PK, Hsu HY, Wang PY. Transient global amnesia after taking sibutramine: a case report. Neurologist. 2010;16:129-131.
Benazzi F. Organic hypomania secondary to sibutraminecitalopram interaction. J Clin Psychiatry. 2002;63:165.
Rocha FF, Bamberg TO, Pinto FC, Gomes LM, Silveira S. Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder. Rev Bras Psiquiatr. 2008;30:400-1.
Şengül C, Balcı-Şengül C. Sibutramine associated depression with suicide preoccupation: two casereports. Anatolian Journal of Psychiatry. 2007;8:234-7.
Eker MC, Onat O, Pirildar S, Ozaskinli S. Case report: A mixed episode induced by Sibutramine. Bull Clin Psychopharmacol. 2003;13:129-32.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.